At these low prices I would expect Crestview to scoop up all the shares that are available. This is chump change for them. Friday trading should be interesting.
Agree. This will get out and IMUC PPS will appreciate. Y/E tax loss selling will reverse and the good ole January affect should work in IMUC's favor going forward.
Hey, I'm trying to educate you! Here's the official Wikipedia definition: "Public float or free float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection (than entire market capitalization) of what public investors consider the company to be worth." And in my reference you can refer to the company getting 50M shares as the "controlling-interest investors".
In my reference, I stated that if 50M shares were give to a Company, for let's say 100M dollars, those shares would NOT be in the "float" used in trading. They would be included in the Outstanding shares, but not the trading float. You are now educated!
It's almost like IMUC didn't want the stock price to surge.......yet. Partnership/Merger/Buyout coming. No clue at this point.
Google promising-subgroup-data-leads-to-phase-iii-immunotherapy-study-for-gbm for the "official" release from Onc Live
Phase II findings have shown a substantial improvement in overall survival (OS) with the dendritic vaccine ICT-107 in a subgroup of patients with HLA-A2+ newly diagnosed glioblastoma multiforme (GBM), warranting further exploration in a phase III study, according to data presented at the 2015 Society for Neuro-Oncology Annual Meeting.
The subgroup of patients showed substantial improvement in overall survival (OS) with the immunotherapy due to an immune response to ICT-107 by enzyme-linked immunospot (ELISPOT). In the group of responders from the phase II study, the median OS was 23.1 months compared with 13.7 months in non-responders (P = .0674). For responders, OS was extended by 52% compared with 29% in non-responders (P = .0615). Progression-free survival (PFS) was extended by 41% versus 15% in non-responders (P = .0259).
“ICT 107 is a dendritic cell peptide vaccine that has shown promising results in a randomized phase II study in patients with newly-diagnosed glioblastomas and was very well-tolerated,” said Patrick Y. Wen, MD, director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, told Targeted Oncology. “If the recently launched phase III study confirms these findings, it will bring a much-needed treatment to our patients.
Relax on the additional shares......Need some dry power, just in case. Just in case a BOY boy wants a HUGE piece of the action. Like....give me 50M shares and I'll give you 100M dollars. Any way, those shares, "if" issued to a BIG boy, won't be in the float.
16:00:00 $ .1900 100
15:59:43 $ .1931 482
Time to play with the boys!!!! I'm in
And 14 months, living longer, is 14 months closer to better/improved therapy or even better.
"Because only 8% of the authorized shares remain available for issuance, our Board of Directors believes it is in the best interests of the Company and our stockholders to increase our authorized shares of common stock in order to have additional authorized shares available for use as our Board of Directors deems appropriate or necessary. For example, such shares may be needed in the future in connection with acquiring another company or its business or assets, establishing a strategic relationship with a corporate partner or raising additional capital. The Board of Directors has no present agreement, arrangement, plan or understanding, however, with respect to the issuance of any such additional shares of common stock.
Although, at present, the Board of Directors has no plans to issue the additional authorized shares of common stock, it desires to have the shares available to provide additional flexibility to use its capital stock for business and financial purposes in the future. The additional shares may be used for various purposes without further stockholder approval. These purposes may include raising capital; providing equity incentives to employees, officers or directors; establishing strategic relationships with other companies; expanding the Company’s business or product lines through the acquisition of other businesses or products; and other purposes."
Nope, you don't get it! From Radio World:
“It’s absurd to talk about bankruptcy with this company this year or in 2016,” said Andrew Gadlin, an analyst with Odeon Capital Group. “Cumulus has enough free cash flow going for it to survive. Their revenue will be about $1.2 billion in 2015. Berner just has to get the operations side fixed. And they’ll figure out the long-term debt.”
Since there is “no trigger” to put Cumulus into bankruptcy in 2016 or 2017, Gadlin said, expect Cumulus to be stable for at least several more years.
“Most of the Cumulus debt comes due in ’19 and ’20, but it’s low-cost debt with low interest rates, and there are covenants to enable them to buy a few more years to stretch out the debt payments.”
You still don't get it, do you? The "first" part of any debt is not due until May, 2019. Get your calculator out....that's 4 1/2 years. Then, in 2020 more is due. Once the land deals are complete...about a year, that will attack 200M+ of the debt. Cumulus is getting their house in order and I expect them to generate cash (cow) going forward. Note: that last quarter Cumulus "earned" .18 cents a share. Yea, the Rdio write down is what novices see. Their cash OH when north of 87M. I expect Mary to set things in motion for bond and stock holders when she presents her plan in 1 month to the BOD. Stay tuned.